Oric Pharmaceuticals (ORIC) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Oric Pharmaceuticals (ORIC) has outperformed Verastem (VSTM) over the past year, losing 36.7% versus a loss of 36.7%. Over five years, ORIC leads with a -48.6% price change compared with -80.3% for VSTM. Verastem is the larger company by market cap ($797.7 million vs $764.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORIC | VSTM |
|---|---|---|
| Share price | $7.36 | $6.33 |
| Market cap | $764.94M | $797.67M |
| 1-day change | -4.42% | -7.73% |
| YTD return | -10.02% | -18.01% |
| 1-year return | -36.66% | -36.70% |
| 5-year return | -48.64% | -80.32% |
| EPS (TTM) | $-1.44 | $-1.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $30.91M |
| Revenue growth (YoY) | — | +209.14% |
| Net income (latest FY) | $-129.47M | $-209.47M |
| Operating margin | — | -550.33% |
| Net margin | — | -677.59% |
| 52-week high | $14.68 | $10.82 |
| 52-week low | $7.23 | $3.43 |
| Distance from 52-week high | -49.86% | -41.50% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +194.97% | +172.04% |
| Average volume | 1.59M | 3.53M |
| Shares outstanding | 103.93M | 126.01M |
| Employees | 111 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Oric Pharmaceuticals
ORIC stock →ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
ORIC vs VSTM FAQ
Which is bigger, Oric Pharmaceuticals or Verastem?
Verastem (VSTM) is larger, with a market capitalization of $797.67M compared with $764.94M for Oric Pharmaceuticals (ORIC).
Which stock has performed better over the past year, ORIC or VSTM?
ORIC returned -36.66% over the past 12 months, compared with -36.70% for VSTM (price return, excluding dividends). Past performance does not predict future results.
Are Oric Pharmaceuticals and Verastem in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.